EDAP TMS CE-marks ultrasound prostate cancer treatment:
This article was originally published in Clinica
EDAP TMS has CE-marked its high intensity focused ultrasound technology for treating localised prostate cancer. Incorporated in the company's Ablatherm device, the minimally invasive technology uses a focused ultrasound beam to destroy tumours without damaging surrounding tissue.
You may also be interested in...
The director of adult immunizations at Johns Hopkins International Vaccine Access Center talks to Scrip about undertaking a massive COVID-19 vaccination effort in the US.
P&G’s oral care business drove 35% of total category market growth in the firm’s fiscal 2020 and exemplifies its growth strategy for all segments – grow entire categories rather than take competitors’ market share, says CFO Jon Moeller.
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.